PureTech Health (LON:PRTC) Stock Price Up 9.8% - Here's Why

Key Points

• PureTech Health plc shares rose by 9.8% during trading, reaching a high of GBX 117.80 ($1.60) from a previous close of GBX 106.40 ($1.44).
• The company's market capitalization is £281 million, with a price-to-earnings ratio of 683.94 and a debt-to-equity ratio of 45.82.
• Insider Bharatt Chowrira purchased 167,739 shares at an average cost of GBX 1 per share, representing a significant insider investment.

PureTech Health plc (LON:PRTC - Get Free Report) traded up 9.8% on Friday . The company traded as high as GBX 117.80 ($1.59) and last traded at GBX 116.80 ($1.58). 1,400,042 shares changed hands during mid-day trading, an increase of 89% from the average session volume of 739,712 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The firm has a market capitalization of £303.07 million, a P/E ratio of 737.65 and a beta of 1.02. The stock has a fifty day moving average price of GBX 129.31 and a two-hundred day moving average price of GBX 129.65.

Insider Buying and Selling

In related news, insider Bharatt Chowrira acquired 167,739 shares of the stock in a transaction that occurred on Thursday, July 3rd. The stock was purchased at an average cost of GBX 1 per share, for a total transaction of £1,677.39. 13.13% of the stock is currently owned by insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.